Stay updated on Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.

Latest updates to the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page
- Check2 days agoChange DetectedThe page now displays a new revision note 'Revision: v3.3.4' and the previous 'Revision: v3.3.3' note was removed.SummaryDifference0.1%

- Check9 days agoNo Change Detected
- Check16 days agoNo Change Detected
- Check23 days agoChange DetectedA new 'Locations' section is added with Pennsylvania listed as a site. The page footer shows revision v3.3.3, and the earlier 'Pennsylvania Locations' entry and 'HHS Vulnerability Disclosure' have been removed.SummaryDifference0.2%

- Check52 days agoChange DetectedRevision updated from v3.2.0 to v3.3.2 on the study page, with no observable changes to study content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check59 days agoChange DetectedRemoval of the funding status notice about government operating status and potential processing delays.SummaryDifference0.4%

- Check74 days agoChange DetectedThe study record shows termination due to slow enrollment and lack of efficacy, with results posted on 2022-10-20.SummaryDifference0.5%

- Check102 days agoChange DetectedUpgrade notice with updated operating status info and a version bump from v3.1.0 to v3.2.0.SummaryDifference4%

Stay in the know with updates to Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Ipilimumab in Mucinous Tumors Clinical Trial page.